225 related articles for article (PubMed ID: 34205590)
1. Ca
Bettaieb L; Brulé M; Chomy A; Diedro M; Fruit M; Happernegg E; Heni L; Horochowska A; Housseini M; Klouyovo K; Laratte A; Leroy A; Lewandowski P; Louvieaux J; Moitié A; Tellier R; Titah S; Vanauberg D; Woesteland F; Prevarskaya N; Lehen'kyi V
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205590
[TBL] [Abstract][Full Text] [Related]
2. Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma.
Schnipper J; Dhennin-Duthille I; Ahidouch A; Ouadid-Ahidouch H
Front Pharmacol; 2020; 11():568993. PubMed ID: 33178018
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer.
Yang J; Liu DJ; Zheng JH; He RZ; Xu DP; Yang MW; Yao HF; Fu XL; Yang JY; Huo YM; Tao LY; Hua R; Sun YW; Kong XM; Jiang SH; Liu W
Cell Oncol (Dordr); 2022 Jun; 45(3):367-379. PubMed ID: 35486320
[TBL] [Abstract][Full Text] [Related]
5. Transportome Malfunctions and the Hallmarks of Pancreatic Cancer.
Ling Q; Kalthoff H
Rev Physiol Biochem Pharmacol; 2021; 181():105-127. PubMed ID: 32770395
[TBL] [Abstract][Full Text] [Related]
6. Kindlin-2 induced by TGF-β signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9.
Zhan J; Song J; Wang P; Chi X; Wang Y; Guo Y; Fang W; Zhang H
Cancer Lett; 2015 May; 361(1):75-85. PubMed ID: 25724625
[TBL] [Abstract][Full Text] [Related]
7. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
[TBL] [Abstract][Full Text] [Related]
9. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
10. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
11. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
12. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.
Hofschröer V; Najder K; Rugi M; Bouazzi R; Cozzolino M; Arcangeli A; Panyi G; Schwab A
Front Pharmacol; 2020; 11():586599. PubMed ID: 33841132
[TBL] [Abstract][Full Text] [Related]
13. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.
Giannuzzo A; Pedersen SF; Novak I
Mol Cancer; 2015 Nov; 14():203. PubMed ID: 26607222
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
17. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
Jiang XY; Zhu QC; Zhang XJ; Duan T; Feng J; Sui XB; Sun XN; Mou YP
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):128-139. PubMed ID: 36543619
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.
Hirakawa T; Yashiro M; Doi Y; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Kimura K; Amano R; Hirakawa K
PLoS One; 2016; 11(8):e0159912. PubMed ID: 27487118
[TBL] [Abstract][Full Text] [Related]
19. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
20. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
